<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02582372</url>
  </required_header>
  <id_info>
    <org_study_id>HCLuisOrtega</org_study_id>
    <nct_id>NCT02582372</nct_id>
  </id_info>
  <brief_title>Subarachnoidal Anesthesia: Dexmedetomidine vs Fentanyl Plus Hyperbaric Bupivacaine for Lower Abdomen Surgery</brief_title>
  <acronym>Dex</acronym>
  <official_title>Subarachnoidal Anesthesia: Dexmedetomidine vs Fentanyl Plus Hyperbaric Bupivacaine for Lower Abdomen Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Central Dr. Luis Ortega</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Central Dr. Luis Ortega</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dexmedetomidine, highly selective agonist for alpha-2 receptors, enhances the sensory and
      motor block with prolonged postoperative analgesia without hemodynamic compromise.

      OBJECTIVE: To evaluate effects of dexmedetomidine vs fentanyl with hyperbaric bupivacaine
      spinal anesthesia for lower abdominal surgeries.

      METHODS: double-blind, randomized, American Society Anesthesiologist classification (ASA) : I
      - II, 18-65 years. F group (23 patients) received 25 mcg fentanyl, Group D (27 patients), 10
      mcg dexmedetomidine with 12.5 mg hyperbaric bupivacaine . 0,02mgrs morphine / kg
      intravenously if EVA≥4was administered in postoperative period. Hemodynamic variables and O2
      saturation intraoperatively was recorded, EVA every 4 hours, side effects, sensory block,
      motor, sedation and peripheral neurological manifestations of toxicity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of baseline blood pressure</measure>
    <time_frame>during anesthesia and 1 hour of postoperatory</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of baseline cardiac rate</measure>
    <time_frame>during anesthesia and 1 hour of postoperatory</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of baseline oxygen saturation</measure>
    <time_frame>during anesthesia and 1 hour of postoperatory</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperatory pain visual analogue scale</measure>
    <time_frame>during first 24 hours of postoperatory</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of motor block using Bromage scale</measure>
    <time_frame>during anesthesia and 1 hour of postoperatory</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numbers of patients with hypotension using non invasive blood presure monitor</measure>
    <time_frame>during anesthesia and first 24 hours of postoperatory</time_frame>
    <description>we report hypotension below 20% of basal values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of patients with excessive sedation using Ramsay scale</measure>
    <time_frame>during anesthesia and first 24 hours of postoperatory</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of patients with nauseas</measure>
    <time_frame>during anesthesia and first 24 hours of postoperatory</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Numbers of patients with signs of peripheral neurological toxicity using questionnaire</measure>
    <time_frame>during first seven days of postoperatory time</time_frame>
    <description>phone contact</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Dexmedetomidine in Subarachnoidal Anesthesia</condition>
  <arm_group>
    <arm_group_label>dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 patients recieve subarachnoidal anesthesia with 12,5 mgrs of bupivacaine 0,5% plus 10 micrograms of dexmedetomidine, with needle 25 gauge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fentanyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 patients recieve subarachnoidal anesthesia with 12,5 mgrs of bupivacaine 0,5% plus 25 micrograms of fentanyl, with needle 25 gauge</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine and bupivacaine</intervention_name>
    <description>10 micrograms of dexmedetomidine plus 12,5 mgrs of bupivacaine subarachnoideal</description>
    <arm_group_label>dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl and bupivacaine</intervention_name>
    <description>25 micrograms of fentanyl plus 12,5 mgrs of bupivacaine subaracnoideal</description>
    <arm_group_label>fentanyl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I and II

          -  lower abdominal surgery

        Exclusion Criteria:

          -  Consumption antagonists adrenergic or channel blockers Ca ++

          -  Patients with arrhythmias or heart block

          -  Allergic to any drugs under study

          -  Obese

          -  Physical or mental incapacity to understand and use the pain scale

          -  Contraindication for anesthesia conductive

          -  Realization difficulty or complication during anesthesia and / or surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2015</study_first_submitted>
  <study_first_submitted_qc>October 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2015</study_first_posted>
  <last_update_submitted>October 20, 2015</last_update_submitted>
  <last_update_submitted_qc>October 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Central Dr. Luis Ortega</investigator_affiliation>
    <investigator_full_name>Beatriz Arismendi Gómez</investigator_full_name>
    <investigator_title>Clinical Professor Beatriz Arismendi Gomez</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 20, 2016</submitted>
    <returned>April 18, 2016</returned>
    <submitted>February 25, 2018</submitted>
    <returned>March 21, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

